Your browser doesn't support javascript.
loading
Structural basis of lipid-droplet localization of 17-beta-hydroxysteroid dehydrogenase 13.
Liu, Shenping; Sommese, Ruth F; Nedoma, Nicole L; Stevens, Lucy Mae; Dutra, Jason K; Zhang, Liying; Edmonds, David J; Wang, Yang; Garnsey, Michelle; Clasquin, Michelle F.
Afiliação
  • Liu S; Medicine Design, Pfizer Inc, Groton, CT, 06340, USA. Shenping.Liu@pfizer.com.
  • Sommese RF; Medicine Design, Pfizer Inc, Groton, CT, 06340, USA. Ruth.Sommese@pfizer.com.
  • Nedoma NL; Medicine Design, Pfizer Inc, Groton, CT, 06340, USA.
  • Stevens LM; Medicine Design, Pfizer Inc, Groton, CT, 06340, USA.
  • Dutra JK; Medicine Design, Pfizer Inc, Cambridge, MA, 02139, USA.
  • Zhang L; Medicine Design, Pfizer Inc, Cambridge, MA, 02139, USA.
  • Edmonds DJ; Discovery Chemistry, Merck Research Laboratories, Cambridge, MA, USA.
  • Wang Y; Medicine Design, Pfizer Inc, Cambridge, MA, 02139, USA.
  • Garnsey M; Medicinal Chemistry, Roche, Basel, Switzerland.
  • Clasquin MF; Medicine Design, Pfizer Inc, Cambridge, MA, 02139, USA.
Nat Commun ; 14(1): 5158, 2023 08 24.
Article em En | MEDLINE | ID: mdl-37620305
ABSTRACT
Hydroxysteroid 17-beta-dehydrogenase 13 (HSD17B13) is a hepatic lipid droplet-associated enzyme that is upregulated in patients with non-alcoholic fatty liver disease. Recently, there have been several reports that predicted loss of function variants in HSD17B13 protect against the progression of steatosis to non-alcoholic steatohepatitis with fibrosis and hepatocellular carcinoma. Here we report crystal structures of full length HSD17B13 in complex with its NAD+ cofactor, and with lipid/detergent molecules and small molecule inhibitors from two distinct series in the ligand binding pocket. These structures provide insights into a mechanism for lipid droplet-associated proteins anchoring to membranes as well as a basis for HSD17B13 variants disrupting function. Two series of inhibitors interact with the active site residues and the bound cofactor similarly, yet they occupy different paths leading to the active site. These structures provide ideas for structure-based design of inhibitors that may be used in the treatment of liver disease.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Hepatopatia Gordurosa não Alcoólica / 17-Hidroxiesteroide Desidrogenases / Neoplasias Hepáticas Limite: Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Hepatopatia Gordurosa não Alcoólica / 17-Hidroxiesteroide Desidrogenases / Neoplasias Hepáticas Limite: Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos